DGAP-News: PAION AG / Key word(s): Change of Personnel
PAION AG: NEW SUPERVISORY BOARD MEMBER APPOINTED
05.11.2012 / 15:27
---------------------------------------------------------------------
PAION AG: NEW SUPERVISORY BOARD MEMBER APPOINTED
Dr Karin Dorrepaal succeeds Dr Harald F. Stock
Aachen (Germany), 05 November 2012 - The biopharmaceutical company PAION AG
(ISIN DE000A0B65S3; Frankfurt Stock Exchange General Standard: PA8)
announced today that the Court of Aachen followed an unanimous proposal by
the Supervisory Board and Management Board of PAION to appoint Dr. Karin
Dorrepaal to the Supervisory Board of PAION, effective as of 29 October
2012. Dr Karin Dorrepaal succeeds Dr Harald F. Stock who resigned from his
position because of possible overlapping interests due to the current
strategic transformation of PAION into a specialty pharmaceutical company
in the anaesthesia field. Dr. Stock was Vice Chairman of the Supervisory
Board of PAION AG since May 2011.
Dr Karin Dorrepaal has broad experience in the Life Science Industry.
Between 2004 and 2006, she was a member of the Management Board of Schering
AG in Berlin. From 1990 to 2004 she worked as management consultant at Booz
Allen & Hamilton in Amsterdam and New York. From 1985 until 1988 she was a
Ph. D. Research Fellow at The Netherlands Cancer Institute in Amsterdam.
'We are delighted Dr Karin Dorrepaal, an recognized expert in the Life
Science Industry, is joining us as a new member of the Supervisory Board ',
said Dr. Jörg Spiekerkötter, Chairman of the Supervisory Board of PAION AG.
He commented further: 'We would like to thank Dr Stock, who has provided a
significant and valuable contribution to the successful strategic
realignment of PAION.'
Dr Stock, Chief Executive Officer of Grünenthal, said: 'I am pleased that I
could contribute to PAION's strategic realignment, from a purely
developmental company towards a specialized pharmaceutical company with
focus on anaesthesia. Anaesthesia is a highly attractive market and I am
convinced that PAION will be successful with their lead compound
Remimazolam. Considering Grünenthal's leadership position in the innovative
pain market sooner or later overlapping interests of both companies may
become probably unavoidable. I am therefore delighted that with Karin
Dorrepaal we have found an experienced executive as my replacement on the
board. I sincerely wish PAION and Dr. Dorrepaal success for the future.'
###
About PAION
PAION is headquartered in Aachen, Germany and has a second site in
Cambridge, UK. The company is specialised in developing innovative drugs
for the hospital-based treatment in indications for which there is a
substantial unmet medical need. PAION is extending its 'Search & Develop'
business model, by transforming into a 'Specialty Pharma Company', with a
focus on anaesthesia products.
Contact
Ralf Penner
Director Investor Relations / Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen - Germany
Phone: +49 241 4453-152
E-mail: r.penner@paion.com
www.paion.com
Disclaimer:
This release contains certain forward-looking statements concerning the
future business of PAION AG. These forward-looking statements contained
herein are based on the current expectations, estimates and projections of
PAION AG's management as of the date of this release. They are subject to a
number of assumptions and involve known and unknown risks, uncertainties
and other factors. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ materially from any
future results and developments expressed or implied by such
forward-looking statements. Considering the risks, uncertainties and other
factors involved, recipients should not rely unreasonably upon these
forward-looking statements. PAION AG has no obligation to periodically
update any such forward-looking statements to reflect future events or
developments.
End of Corporate News
---------------------------------------------------------------------
05.11.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: PAION AG
Martinstr. 10-12
52062 Aachen
Germany
Phone: +49 (0)241-4453-0
Fax: +49 (0)241-4453-100
E-mail: info@paion.com
Internet: www.paion.com
ISIN: DE000A0B65S3
WKN: A0B65S
Listed: Regulierter Markt in Frankfurt (General Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
191510 05.11.2012
DGAP-News: PAION AG: NEW SUPERVISORY BOARD MEMBER APPOINTED
| Source: EQS Group AG